Peripartum cardiomyopathy: Euro Observational Research Program.

M F Hoes,F Russo,D J Van Veldhuisen,M P Van Den Berg,K Y Van Spaendonck-Zwarts,I Van Hagen,P Van Der Meer,J Roos-Hesselink

doi:10.1007/s12471-014-0573-5

Abstract

Peripartum cardiomyopathy is a rare but potentially life-threatening form of heart failure affecting women late in pregnancy or in the first months after delivery. Peripartum cardiomyopathy is difficult to diagnose and its onset and progression are variable between individuals. The pathophysiology remains poorly understood, hence treatment options are limited and possibly harmful to the foetus. Furthermore, geographical incidence varies greatly and little is known about the incidence in Western countries. To gain further understanding of the pathophysiology and incidence of peripartum cardiomyopathy, the European Society of Cardiology initiated a study group to implement a registry. This review provides an overview of current insights into peripartum cardiomyopathy, highlights the need for such a registry and provides information about this Euro Observational Research Program.

Highlights

Peripartum cardiomyopathy is a rare but potentially lifethreatening form of heart failure affecting women late inM
This review provides an overview of current insights into peripartum cardiomyopathy, highlights the need for such a registry and provides information about this Euro Observational Research Program
Blocking miR-146a with a specific antagomir causes the attenuation of peripartum cardiomyopathy clinical features in STAT3 conditional knockout mice, without affecting fulllength prolactin-dependent milk production functions [10]

Summary

Introduction

Peripartum cardiomyopathy is a rare but potentially lifethreatening form of heart failure affecting women late inM. In pregnant PGC-1α knockout mice, the 16 kDa prolactin-induced antiangiogenic effect and the inhibition of proangiogenic factors act together towards the development of a very severe form of peripartum cardiomyopathy. Blocking miR-146a with a specific antagomir causes the attenuation of peripartum cardiomyopathy clinical features in STAT3 conditional knockout mice, without affecting fulllength prolactin-dependent milk production functions [10].

Results

Conclusion